BackDurect Overview

Durect EBIT

Latest ebit for DRRX: $-15M, below the Healthcare sector average of $22B.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$2.27M
33.46% YoY

As of Jun 30, 2025

Annual EBIT (TTM)

-$14.99M
39.86% YoY

Trailing 12 months ending Jun 30, 2025

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Durect (DRRX) FAQ

As of the most recent data (June 2025), DRRX shows a EBIT of $-15M. That compares with $-25M in the prior-year period — up 39.9% year over year. That is below the Healthcare sector average of $22B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, DRRX's EBIT is now $-15M (was $-25M) — a 39.9% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Durect is outperforming or lagging.

The Healthcare sector average EBIT is about $22B. Durect is at $-15M, which is lower that average. That is roughly 100.1% below the sector mean. Use the comparison chart on this page to see how DRRX stacks up against individual peers as well.

Tracking DRRX's ebit over time shows whether Durect is scaling, shrinking, or reshaping that part of the business. The current reading is $-15M That compares with $-25M in the prior-year period — up 39.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Durect's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-15M) with ownership activity and broader fundamentals.